Steven M. Klosk

Steven Klosk has spent over 25 years in the pharmaceutical CDMO industry. Most recently, Steve was the CEO of Cambrex Corporation for twelve years until he retired in 2020 after leading the sale of Cambrex to Permira, a leading global private equity firm at an enterprise value of $2.5B. Under Steve’s leadership, Cambrex became a leading global, fully integrated supplier of drug substances, drug product and testing services across the entire drug life cycle to both the innovator and generic pharmaceutical markets. Through significant organic investments and M&A Cambrex grew into a network of twelve manufacturing and R&D sites in the USA and Europe with over 2,000 employees. Full year revenues in 2019 were approximately $650M. In addition to serving on the NJ Bio board he is a member of the Board of Directors of Recipharm, a leading European-based pharmaceutical CDMO and Caladrius Biosciences a publicly traded cell therapy drug development biotech company. Steve graduated with a BS degree in Industrial & Labor Relations from Cornell University and a JD from New York Law School.